Navigation Links
Protein could offer target to reduce lung damage from smoking-caused emphysema
Date:5/16/2011

An international research team has identified a lung protein that appears to play a key role in smoking-related emphysema and have crafted an antibody to block its activity, Indiana University scientists reported.

The research, conducted in mice, suggests that the protein, a cytokine named EMAPII, could provide a target for drugs to treat emphysema, said Irina Petrache, M.D., associate professor of medicine at the Indiana University School of Medicine. The research was posted online May 16 for the June edition of The Journal of Clinical Investigation.

Emphysema, a form of chronic obstructive pulmonary disease (COPD) that affects nearly 5 million people in the U.S alone, is caused by the destruction of cells that transfer oxygen from the lungs to the blood, along with inflammation in the lungs. Cigarette smoking is the most common cause of emphysema.

The cytokine EMAPII a type of cell-signaling molecule is normally part of the process of early lung development. Research had previously found that EMAPII could cause the death of cells that line blood vessels endothelial cells and inflammation, but it had not been identified as the molecular culprit at work when cigarette smoking inflicted its damage on the lungs.

"The fact that we could have a single target affecting two major processes made us excited about looking for it in response to smoking," said Dr. Petrache, the Floyd and Reba Smith Investigator in Respiratory Disease at IU.

When the researchers induced emphysema in mice exposed to cigarette smoke, tests showed the mice had elevated levels of the EMAPII cytokine. In other tests, the scientists also found elevated levels of the cytokine in the lungs of patients with COPD.

The researchers also found that the cell death caused by the EMAPII resulted in the release of enzymes that cause more production of EMAPII, causing a vicious cycle of elevated cytokine levels and more cell death.

Members of the research team, led by first author Matthias Clauss, Ph.D., IU associate research professor of cellular and integrative physiology, created an antibody designed to specifically target EMAPII and block its activity. The mice received an inhaled version of the antibody during their third month of smoking. They then were exposed to a fourth month of smoking without the treatment.

The mice receiving the treatment had significantly less cell death and inflammation and improved lung function compared to the smoking mice who did not receive the treatment. Moreover the benefits to the treated mice continued even after the treatment stopped.

Next steps include optimizing the duration of the antibody treatments to determine whether they continue to have an effect after the animals have stopped smoking, she said. Plans also call for work to measure levels of the cytokine in large numbers of human emphysema and COPD patients to determine whether it can be used as a biomarker to measure the presence, severity or type of lung disease.

Considerable research work remains before an EMAPII antibody might be ready for testing in humans, Dr. Petrache said.


'/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Related biology news :

1. UT Southwestern researchers find protein that might be key to cutting cancer cells blood supply
2. Researchers show heparan sulfate adjusts functions of growth factor proteins
3. Weizmann Institute scientists discover: A protein that contributes to obesity
4. Illinois professor chairs committee that recommends immediate calories, protein for TBI
5. Several baffling puzzles in protein molecular structure solved with new method
6. Discovery identifies elaborate G-protein network in plants
7. Researchers combine active proteins with material derived from fruit fly
8. Researchers get a first look at the mechanics of membrane proteins
9. Polarized microscopy technique shows new details of how proteins are arranged
10. Secrets of a precision protein machine
11. Starch-controlling gene fuels more protein in soybean plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... ... that exhibits both viscous and elastic characteristics when deformed, which is identical to ... properties to gently absorb compressive forces and return to its natural state along ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology: